Fennec Pharmaceuticals (FENC) Q1 2024 Earnings
FENC·Reported May 14, 2024·Before market open
Fennec Pharmaceuticals reported Q1 2024 revenue of $25.4M, beat analyst consensus of $18.9M by $6.5M. Diluted EPS came in at $0.47, beat the $0.26 consensus by $0.21.
Revenue
$25.4Mbeat by $6.5M
Consensus: $18.9MDiluted EPS
$0.47beat by $0.21
Consensus: $0.26
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Fennec Pharmaceuticals's Q1 2024 earnings report.
Fennec Pharmaceuticals (FENC) reported Q1 2024 earnings on May 14, 2024 before market open.
Fennec Pharmaceuticals reported revenue of $25.4M and diluted EPS of $0.47 for Q1 2024.
Revenue beat the consensus estimate of $18.9M by $6.5M. EPS beat the consensus estimate of $0.26 by $0.21.
You can read the 10-Q periodic report (0001558370-24-008162) directly on SEC EDGAR. The filing index links above go to sec.gov.